Navigation Links
New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
Date:7/6/2009

LEIDEN, The Netherlands, July 6 /PRNewswire/ -- Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammatory diseases, have a total budget of nearly 6 million euros.

The new consortium, formed by Syncom, Synvolux Therapeutics, and University Medical Center Groningen, focuses on designing a versatile drug delivery system for inflammatory diseases and cancer. Another new consortium is formed by InteRNA Technologies, Utrecht University and VU University Medical Center, and focuses on the development of anti-angiogenic microRNA-based therapeutic products for the treatment of cancer.

Versatile drug delivery platform for inflammatory diseases and cancer

New molecular entities (NMEs) in the drug development pipeline comprise various classes of kinase inhibitors that cause unacceptable toxicity in humans. Proper formulation might circumvent side effects and improve their general therapeutic efficacy. However, currently, no appropriate formulation technology is available for these kinase inhibitors.

This project focuses on a systematic approach in which chemical modification of NMEs is combined with drug formulation studies. This will lead to a versatile drug delivery platform for future clinical application of kinase inhibitors in the treatment of cancer and chronic inflammatory diseases. "This approach is expected to make targeted drug delivery finally meet its expectations, as it will become available for a variety of drug classes that are under development in the pharmaceutical industry," according to the consortium members.

Development of novel anti-angiogenic miRNA based therapeutics

"Conventional cancer treatment such as surgery, radiation therapy and chemotherapy are far from sufficient, therefore, new strategies of cancer treatment are needed more than ever," says Roel Schaapveld, Chief Executive Officer, InteRNA. There is a large body of evidence indicating that tumor growth and metastasis formation are dependent on the formation of new blood vessels. Furthermore, angiogenesis is an early event in the development of tumors, being already switched on in pre-cancerous events and long before visible or clinically relevant tumor mass is present. Schaapveld: "These two features make angiogenesis an ideal target for the development of novel anti-cancer strategies."

The recent discovery that non-coding RNAs, called microRNAs (miRNAs), play a critical role in gene regulation provides new opportunities to discover RNAs that can control angiogenesis. The major aim of this project is to establish a technology platform for the development of (anti-cancer) therapeutics based on angiostatic miRNAs. miRNA is utilized as a therapeutic modality and advanced nanoparticle delivery systems accomplish intracellular delivery of nucleic acid agents. These will be combined with the identification of surface receptor targets on tumor blood vessels to allow for therapeutic intervention. Eventually, this will result in the development of anti-angiogenic miRNA-based therapeutic products for the treatment of cancer.


'/>"/>
SOURCE TI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
2. Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM)
3. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
4. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
5. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
6. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
7. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
9. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
10. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
11. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
(Date:12/5/2016)... , Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., ... presented data from two Phase I trials evaluating ... the 58th annual meeting of the American Society ... California . The two datasets show encouraging ... myeloid leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell ...
(Date:12/5/2016)... YORK, Pa. , Dec. 5, 2016  Pennsylvania ... of Drug and Alcohol Programs Gary Tennis ... reversal drug, at Minnich,s Pharmacy in York ... standing order signed by Dr. Levine as a prescription ... "It,s important to remember that any ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... It can ... holiday presents for their four-legged family members as they do for their human friends ... pet parents’ desire to find the highest quality and most innovative pet products has ...
(Date:12/6/2016)... GA (PRWEB) , ... December 06, 2016 , ... ... and the impact of new federal healthcare regulations at the 7th annual Health ... Centre, Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare & ...
(Date:12/6/2016)... ... 2016 , ... The V Foundation for Cancer Research, a ... to Lose fundraising campaign. As the V Foundation’s boldest initiative to date, Not ... The campaign aims to raise $200 million by 2020 and strategically fund emerging, ...
(Date:12/6/2016)... ... 2016 , ... Just in time for the holiday season, the celebrated paleo ... for Honeyville’s new Organic Quinoa Flour product for sale at Costco stores throughout the ... , “I think it’s wonderful that a growing number of retailers such as ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This ... label design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, ...
Breaking Medicine News(10 mins):